Hikma acquires Egyptian Pharmaceuticals for $22.2m
Complex Made Simple

Hikma acquires Egyptian Pharmaceuticals for $22.2m

Hikma acquires Egyptian Pharmaceuticals for $22.2m

UK-headquartered Hikma Pharmaceuticals has agreed to buy Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI) for around $22.2m in cash to boost its position in the Egyptian market, Bloomberg has reported. The acquisition of EPCI will add a portfolio of 35 products in 46 dosages and strengths, including three cephalosporin anti- infection brands for the Egyptian market, Hikma said. "Since we entered the Egyptian market in 2007, we have been rapidly growing our presence," said the CEO of Hikma, Said Darwazah said. "This acquisition will further accelerate that growth."

    Author
    AMEinfo Staff

    AMEinfo staff members report business news and views from across the Middle East and North Africa region, and analyse global events impacting the region today.

    © 2021, ADigitalcom. All rights reserved